Literature DB >> 22822508

Antibody delivery of drugs and radionuclides: factors influencing clinical pharmacology.

Saileta Prabhu1, C Andrew Boswell, Douglas Leipold, Leslie A Khawli, Dongwei Li, Dan Lu, Frank-Peter Theil, Amita Joshi, Bert L Lum.   

Abstract

The therapeutic rationale of antibody conjugates is the selective delivery of a cytotoxin to tumor cells via binding and internalization of the monoclonal antibodies to a specific cell-surface antigen, thereby enhancing the therapeutic index of the cytotoxin. The key structural and functional components of an antibody conjugate are the antibody, the linker and the cytotoxin (chemical or radionuclide) with each component being critical for the successful development of the conjugate. Considerable efforts have been made in understanding the pharmacokinetics, pharmacodynamics, tissue distribution, metabolism and pharmacologic effects of these complex macromolecular entities. The purpose of this article is to discuss the properties and various structural components of antibody conjugates that influence their clinical pharmacology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22822508     DOI: 10.4155/tde.11.41

Source DB:  PubMed          Journal:  Ther Deliv        ISSN: 2041-5990


  9 in total

1.  Compartmental tissue distribution of antibody therapeutics: experimental approaches and interpretations.

Authors:  C Andrew Boswell; Daniela Bumbaca; Paul J Fielder; Leslie A Khawli
Journal:  AAPS J       Date:  2012-05-31       Impact factor: 4.009

2.  Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates.

Authors:  Dan Lu; Sandhya Girish; Yuying Gao; Bei Wang; Joo-Hee Yi; Ellie Guardino; Meghna Samant; Melody Cobleigh; Mothaffar Rimawi; Pierfranco Conte; Jin Yan Jin
Journal:  Cancer Chemother Pharmacol       Date:  2014-06-18       Impact factor: 3.333

3.  An Agent-Based Systems Pharmacology Model of the Antibody-Drug Conjugate Kadcyla to Predict Efficacy of Different Dosing Regimens.

Authors:  Bruna Menezes; Cornelius Cilliers; Timothy Wessler; Greg M Thurber; Jennifer J Linderman
Journal:  AAPS J       Date:  2020-01-15       Impact factor: 4.009

4.  An oncolytic adenovirus regulated by a radiation-inducible promoter selectively mediates hSulf-1 gene expression and mutually reinforces antitumor activity of I131-metuximab in hepatocellular carcinoma.

Authors:  Yan Zhang; Lin Fang; Quan'an Zhang; Qin Zheng; Jinlong Tong; Xiaohui Fu; Xiaoqing Jiang; Changqing Su; Junnian Zheng
Journal:  Mol Oncol       Date:  2012-11-07       Impact factor: 6.603

Review 5.  Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates.

Authors:  Amrita V Kamath; Suhasini Iyer
Journal:  Pharm Res       Date:  2014-12-02       Impact factor: 4.200

6.  Semi-mechanistic Multiple-Analyte Pharmacokinetic Model for an Antibody-Drug-Conjugate in Cynomolgus Monkeys.

Authors:  Dan Lu; Jin Yan Jin; Sandhya Girish; Priya Agarwal; Dongwei Li; Saileta Prabhu; Randall C Dere; Ola M Saad; Denise Nazzal; Neelima Koppada; Saroja Ramanujan; Chee M Ng
Journal:  Pharm Res       Date:  2014-12-03       Impact factor: 4.200

7.  Integrated Two-Analyte Population Pharmacokinetic Model for Antibody-Drug Conjugates in Patients: Implications for Reducing Pharmacokinetic Sampling.

Authors:  D Lu; L Gibiansky; P Agarwal; R C Dere; C Li; Y-W Chu; J Hirata; A Joshi; J Y Jin; S Girish
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2016-11-10

8.  Functional relevance of in vivo half antibody exchange of an IgG4 therapeutic antibody-drug conjugate.

Authors:  Peter Herbener; Kurt Schönfeld; Martin König; Matthias Germer; Jude M Przyborski; Katrin Bernöster; Jörg Schüttrumpf
Journal:  PLoS One       Date:  2018-04-19       Impact factor: 3.240

Review 9.  Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer.

Authors:  Bryan D Fleming; Mitchell Ho
Journal:  Toxins (Basel)       Date:  2016-09-22       Impact factor: 4.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.